Announcements
Published: 19 December 2025 by Matthew Belfield
As a leading LGBTQ+ health and wellbeing charity, we welcome the MHRA’s approval of lenacapavir for PrEP – a major step forward in HIV prevention.
PrEP is one of the most powerful tools we have to prevent HIV. It saves lives, empowers individuals, and reduces stigma by giving people control over their sexual health. HIV remains a pressing challenge for LGBTQ+ communities and men who have sex with men, and lenacapavir provides a new option to improve access and choice.
Prevention is the cornerstone of achieving zero transmissions by 2030. It is cost-effective, delivers long-term impact, and saves lives—but it requires sustained investment, resources, and commitment. We welcome conversations with partners, funders, and policymakers who are ready to act and make HIV prevention a priority.
“This approval is a game-changer for HIV prevention. Lenacapavir gives people more choice, more control, and more hope. But we know progress cannot happen in isolation – ending new HIV transmissions by 2030 will take national collaboration, shared resources, and sustained investment. As a leading LGBTQ+ health and wellbeing charity, we are committed to working with partners across the country to make HIV prevention a top priority.” – Dr. Paul Martin OBE, Chief Executive of LGBT Foundation
